marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-14-2024
Brainstorm Cell Therapeutics Financial Ratios 2011-2024 | BCLI
Annual Financial Ratios Brainstorm Cell Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-1.9 | -2.8 | -5.9 | -5.9 | -3.8 | -5.3 | -13.7 | -10.3 | -5.4 | -5.9 | -8.9 | -9.2 | -6.7 |
P/S |
- | - | - | - | - | - | - | - | - | - | - | - | - |
EPS |
-0.4 | -0.7 | -0.7 | -1.1 | -1.1 | -0.7 | - | - | - | - | - | - | - |
EV (Enterprise Value) |
39.6 M | 77.5 M | 136 M | 166 M | 106 M | 78.9 M | 70.7 M | 51.6 M | 48 M | 53.5 M | 42 M | 31.7 M | 25.8 M |
EBITDA per Share |
-0.49 | -0.67 | -0.67 | -1.01 | -1.04 | -0.698 | -0.262 | -0.268 | -0.464 | -0.543 | -0.467 | -0.384 | -0.467 |
EV/EBITDA |
-5.6 | -4.8 | -3.8 | -5.2 | -13.3 | -10.1 | -5.3 | -6.8 | -8.0 | -8.6 | -6.5 | ||
PEG |
0.65 | -0.08 | -0.17 | 0.16 | 0.07 | 0.03 | -3.69 | -0.25 | -0.17 | 0.12 | 0.18 | -0.28 | 2.32 |
P/B |
-6.6 | -22.2 | 7.5 | 5.3 | -7.2 | 14.7 | 11.5 | 5.2 | 3.2 | 8.2 | 15.9 | 7.9 | 17.8 |
P/CF |
-1.6 | -3.5 | -5.5 | -5.3 | -7.5 | -5.8 | -26.6 | -8.6 | -6.1 | -11.7 | -10.4 | -10.5 | -11.6 |
ROE % |
353.89 | 805.21 | -126.45 | -89.70 | 190.24 | -278.07 | -84.22 | -50.31 | -60.08 | -138.52 | -178.86 | -86.14 | -263.31 |
ROA % |
-408.56 | -287.27 | -83.54 | -62.06 | -355.88 | -124.23 | -43.35 | -46.28 | -49.70 | -93.29 | -103.66 | -64.60 | -142.78 |
ROCE % |
596.85 | 7112.32 | -106.88 | -79.16 | 206.84 | -280.36 | -85.02 | -51.33 | -60.42 | -109.16 | -147.85 | -84.34 | -242.01 |
Current Ratio |
0.5 | 0.7 | 2.9 | 3.8 | 0.2 | 1.7 | 1.7 | 12.1 | 5.7 | 3.1 | 3.3 | 4.3 | 2.0 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Brainstorm Cell Therapeutics
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.04 | -0.05 | - | -0.03 | -0.13 | -0.14 | - | -0.19 | -0.19 | -0.15 | - | -0.15 | -0.17 | -0.19 | - | -0.14 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.04 | -0.04 | - | -0.13 | -0.14 | -0.14 | - | -0.19 | -0.21 | -0.15 | - | -0.14 | -0.17 | -0.19 | - | -0.14 | -0.25 | -0.29 | - | -0.25 | -0.22 | -0.23 | - | -0.15 | -0.16 | -0.12 | - | -0.13 | -0.06 | -0.09 | - | -0.09 | -0.05 | -0.1 | - | -0.14 | -0.13 | -0.12 | - | -0.16 | -0.1 | -0.18 | - | -0.1 | -0.01 | -0.01 | - | -0.01 | -0.01 | -0.01 | - | -0.01 | 0.01 | 0.01 |
ROE % |
228.29 | 293.52 | 289.28 | -204.81 | -746.39 | -973.34 | -620.77 | -642.18 | -169.50 | -100.59 | -60.59 | -73.24 | -64.49 | -64.56 | -56.38 | -10.29 | 48.46 | 259.55 | 426.57 | 148.50 | -175.66 | -643.97 | -834.21 | -918.43 | -724.58 | -530.72 | -252.65 | -302.97 | -269.06 | -235.16 | -150.94 | -211.02 | -220.78 | -230.55 | -180.24 | -318.75 | -397.19 | -475.63 | -415.55 | -594.41 | -634.76 | -675.10 | -536.58 | -622.72 | -530.00 | -437.27 | -258.41 | -521.72 | -698.89 | -876.06 | -789.92 | -263.31 | -263.31 | -263.31 |
ROA % |
-189.45 | -237.46 | -178.57 | -230.31 | -260.48 | -204.89 | -109.66 | -125.11 | -88.82 | -66.52 | -44.01 | -52.76 | -46.07 | -45.65 | -39.01 | -125.24 | -202.71 | -544.16 | -797.98 | -922.20 | -960.20 | -728.55 | -372.68 | -416.03 | -335.15 | -254.28 | -130.05 | -176.33 | -179.25 | -182.18 | -138.83 | -188.52 | -191.94 | -195.36 | -149.09 | -242.38 | -285.97 | -329.57 | -279.87 | -383.53 | -393.90 | -404.27 | -310.98 | -375.58 | -336.51 | -297.45 | -193.79 | -336.57 | -414.76 | -492.95 | -428.35 | -142.78 | -142.78 | -142.78 |
ROCE % |
2108.43 | 2240.22 | 1426.74 | 1267.87 | 164.56 | -184.04 | -256.89 | -275.28 | -134.80 | -84.42 | -53.46 | -64.67 | -57.48 | -58.06 | -50.45 | -0.53 | 60.59 | 122.76 | 137.91 | 73.48 | -40.87 | -146.09 | -171.97 | -212.65 | -188.90 | -145.64 | -89.06 | -105.61 | -81.47 | -73.11 | -44.77 | -62.97 | -64.62 | -71.42 | -50.53 | -86.28 | -103.82 | -106.13 | -85.83 | -117.68 | -113.79 | -138.95 | -107.93 | -136.81 | -133.84 | -110.46 | -71.50 | -118.14 | -135.90 | -41.69 | 74.13 | -46.64 | 73.39 | 47.38 |
Current Ratio |
0.6 | 0.4 | 0.5 | 0.7 | 0.6 | 0.6 | 0.7 | 1.1 | 1.7 | 2.3 | 3.0 | 3.6 | 3.5 | 3.9 | 3.2 | 3.2 | 3.2 | 3.2 | 0.3 | 0.3 | 0.3 | 0.3 | 1.8 | 1.8 | 1.8 | 1.8 | 2.1 | 2.1 | 2.1 | 2.1 | 12.5 | - | - | - | 5.8 | 6.0 | 6.8 | 6.3 | 3.1 | 3.1 | 3.1 | 3.1 | 2.4 | 2.4 | 2.4 | 2.4 | 4.4 | 4.0 | 4.0 | 4.0 | 2.2 | 2.2 | 2.2 | 2.2 |
DSO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DIO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
DPO |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash Conversion Cycle |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency